Almirall

Time: 18.00 – 19.00
Room: Auditorium Lumière

"MS spasticity symptoms management.  Endocannabinoid system modulator data beyond clinical trials"
Chair: M. Trojano (IT)

Presentation 1: MS Spasticity daily management, retrospective data from EU
T.M. Berger (AT)
Content:
- 5E / 6E retrospective study and patients’ survey in Spain data
- MOVE I Germany retrospective study data
- MOVE I EU (ongoing)

Presentation 2: Endocannabinoid system modulator use in the everyday clinical practice in UK and Spain
J.A. García Merino (ES)
Content:
- Introduction about MS Spasticity treatment CT data
- Risk Management Plan items
- Review of the UK and Spain Registries first data
  - UK: > 300 patients data: Tolerability (cognition, driving ability...), doses
  - Spain: 100 first patients on the registry tolerability, maintenance of treatment.

Presentation 3: A new MS spasticity treatment option effect in everyday clinical practice and cost-effectiveness in Germany
P. Flachenecker (DE)
Content:
- MOVE II Germany, data MS Spasticity treatment in MSS: Results of > 400 patients, efficacy and tolerability
- MS Spasticity treatment pharmacoeconomics, model and data from GE

Réservé uniquement aux médecins n’exerçant pas sur le territoire français

Satellite Symposium arranged by Almirall